Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (107)	3/30/1998 1:30:00 PM
From: Quonnie	Read Replies (1) \| Respond to of 642

Henry.LLY is dropping like a rock! How low do you expect it to drop? I am interested in buying but would like to get it on the bottom if possible. I think LLY is a good company and a bright future.Will it get to the mid $50's? thanks quonnie GO LLY!!!

To: Henry Niman who wrote (107)	3/31/1998 12:43:00 PM
From: auco7	Read Replies (2) \| Respond to of 642

These new SERMs will not come to market overnight. Evista's clinical trials on patients (phase 3)where 39 months long!!! Then you must add data crunching time and application process then the typical 12 months for the FDA to approve the drug. So it is likely that these new SERMs will not make it to market until the year 200???. Lilly has a strong pipeline. Extremely promising data on Evista preventing breast cancer reported in the media. Zyprexa is waiting for the bipolar indication anyday now and has 3 more indication in phase 2 and 3. Tomoxetine is in phase 2 for attention deficit. Prozac is in phase 3 studies on 5 new indications including panic, PMS,child and adolescent depression and an extended dosing formulation!!! Gemzar is in phase 2 studies for breast and bladder cancer. Cynt is in phase 3 for congestive heart failure. Parathyroid hormone for osteoporosis, really builds bone like nothing out there, even Fosamax. SERM 3 for osteoporosis and breast cancer in phase 2. Duloxetine in phase 2 for urinary incontinence. It is possible that some of these indications and drugs may not make it to the market but most will. This information is from the 1997 annual report. :-)